FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Real-time Bid/Ask 10:05:15 2024-06-14 EDT | ||
| 52.57 EUR / 53.05 EUR | +38.65% |
|
| Current month | -42.07% | ||
| 1 month | +47.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 45.27 | +18.85% |
| 24-06-13 | 38.09 | +5.19% |
| 24-06-12 | 36.21 | -10.19% |
| 24-06-11 | 40.32 | -14.95% |
| 24-06-10 | 47.41 | -10.09% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 08:56 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SN7D2U |
| ISIN | DE000SN7D2U3 |
| Date issued | 2022-07-28 |
| Strike | 73.58 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 69.09 € |
|---|---|
| Lowest since issue | 1.92 € |
| Spread | 0.48 € |
| Spread % | 0.94% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Certificates
- Certificat
